cliffwatch

vancomycin hydrochloride · Azurity · NDA 208910

Firvanq Kit

Earliest generic entry, as listed · earliest of 2 marketed strengths
13 Mar 2035

Blocked by patent: US 10493028, US 10688046, US 10959946, US 10959947, US 10959947, US 10959948, US 10959948, US 10959949, US 10959949, US 11638692.

Listed patents · 10 unexpired

PatentClaimsExpires
US 10493028product13 Mar 2035
US 10688046product13 Mar 2035
US 10959946product13 Mar 2035
US 10959947product, use U-310513 Mar 2035
US 10959947product, use U-310413 Mar 2035
US 10959948product, use U-310513 Mar 2035
US 10959948product, use U-310413 Mar 2035
US 10959949product, use U-310513 Mar 2035
US 10959949product, use U-310413 Mar 2035
US 11638692product13 Mar 2035

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026Generic approved · 208910-001

Products covered · 2

NDA · productFormStrengthListed expiry
208910 · 001 · RLDfor solution, oralEQ 25MG BASE/ML13 Mar 2035
208910 · 002 · RLDfor solution, oralEQ 50MG BASE/ML13 Mar 2035